Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
CAMBRIDGE, Mass., April 06, 2016 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the upcoming 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 9:20 a.m. ET in New York, NY.
A live webcast of the presentation can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.
For media: Liz Bryan Spectrum Science Communications, Inc. O: 202-955-6222 [email protected] For investors: Jonathan Poole Genocea Biosciences, Inc. O: 617-876-8191 [email protected]
